Key result
Tafamidis evaluation in clinical practice assesses the economic impact of its cost and insurance status.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
This economic evaluation study examines the authors’ experience of prescribing tafamidis in terms of their cost and the insurance status of patients.
No takes yet. Share an insight, caveat, or question.
Masri et al. (2020) studied this question. Tafamidis, the most expensive cardiac medication in history, was evaluated in clinical practice to determine the economic impact of its cost and patient insurance status.
Synapse has enriched 10 related papers. Consider them for comparative context: